WEE1 inhibition and genomic instability in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 227-235

  Vriend, Lianne E M ^a,b,c   De Witt Hamer, Philip C ^a,b   Van Noorden, Cornelis J F ^c   Würdinger, Thomas ^a,b,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Amsterdam Gastroenterology Metabolism   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Cell cycle checkpoint; Chromosomal instability; Genomic instability; P53; WEE1 kinase

Indexed keywords

CARBOPLATIN; DNA; FLUOROURACIL; FUNGAL PROTEIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; MK 1775; PD 0166285; PD 0407824; PROTEIN INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ANEUPLOIDY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CHROMOSOMAL INSTABILITY; COLON CANCER; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEMINOMA;

CANCER; CELL CYCLE CHECKPOINT; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; P53; WEE1 KINASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES;

EID: 84882746097     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.05.002     Document Type: Review

References (84)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Geigl J.B., Obenauf A.C., Schwarzbraun T., Speicher M.R. Defining 'chromosomal instability'. Trends Genet. 2008, 24:64-69.
3. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649.
4. Yamamoto H., Imai K., Perucho M. Gastrointestinal cancer of the microsatellite mutator phenotype pathway. J. Gastroenterol. 2002, 37:153-163.
5. Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum. Mol. Genet. 2001, 10:735-740.
6. Williams G.H., Stoeber K. The cell cycle and cancer. J. Pathol. 2012, 226:352-364.
7. Suijkerbuijk S.J., Kops G.J. Preventing aneuploidy: the contribution of mitotic checkpoint proteins. Biochim. Biophys. Acta 2008, 1786:24-31.
8. Li R., Murray A.W. Feedback control of mitosis in budding yeast. Cell 1991, 66:519-531.
9. May K.M., Hardwick K.G. The spindle checkpoint. J. Cell Sci. 2006, 119:4139-4142.
10. Dobles M., Liberal V., Scott M.L., Benezra R., Sorger P.K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000, 101:635-645.
11. Wang Y., Li J., Booher R.N., Kraker A., Lawrence T., Leopold W.R., Sun Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001, 61:8211-8217.
12. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K., Markowitz S.D., Kinzler K.W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303.
13. Hanks S., Coleman K., Reid S., Plaja A., Firth H., Fitzpatrick D., Kidd A., Mehes K., Nash R., Robin N., Shannon N., Tolmie J., Swansbury J., Irrthum A., Douglas J., Rahman N. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 2004, 36:1159-1161.
14. Weaver B.A., Cleveland D.W. Does aneuploidy cause cancer?. Curr. Opin. Cell Biol. 2006, 18:658-667.
15. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
16. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
17. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344:503-508.
18. Dunphy W.G. The decision to enter mitosis. Trends Cell Biol. 1994, 4:202-207.
19. Santamaria D., Barriere C., Cerqueira A., Hunt S., Tardy C., Newton K., Caceres J.F., Dubus P., Malumbres M., Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448:811-815.
20. Parker L.L., Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
21. Squire C.J., Dickson J.M., Ivanovic I., Baker E.N. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 2005, 13:541-550.
22. Booher R.N., Holman P.S., Fattaey A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J. Biol. Chem. 1997, 272:22300-22306.
23. Mueller P.R., Coleman T.R., Kumagai A., Dunphy W.G. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995, 270:86-90.
24. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 2007, 7:495-507.
25. Okayama H., Nagata A., Igarashi M., Suto K., Jinno S. Mammalian G2 regulatory genes and their possible involvement in genetic instability in cancer cells. Princess Takamatsu Symp. 1991, 22:231-238.
26. Ray D., Kiyokawa H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008, 68:1251-1253.
27. Nurse P. Genetic control of cell size at cell division in yeast. Nature 1975, 256:547-551.
28. Tominaga Y., Li C., Wang R.H., Deng C.X. Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int. J. Biol. Sci. 2006, 2:161-170.
29. Sorensen C.S., Syljuasen R.G. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012, 40:477-486.
30. Beck H., Nahse-Kumpf V., Larsen M.S., O'Hanlon K.A., Patzke S., Holmberg C., Mejlvang J., Groth A., Nielsen O., Syljuasen R.G., Sorensen C.S. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol. Cell. Biol. 2012, 32:4226-4236.
31. Dominguez-Kelly R., Martin Y., Koundrioukoff S., Tanenbaum M.E., Smits V.A., Medema R.H., Debatisse M., Freire R. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J. Cell Biol. 2011, 194:567-579.
32. Morris C., Jalinot P. Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation. Oncogene 2005, 24:1203-1211.
33. Oh J.S., Han S.J., Conti M. Wee1B, Myt1, and Cdc25 function in distinct compartments of the mouse oocyte to control meiotic resumption. J. Cell Biol. 2010, 188:199-207.
34. De Witt Hamer P.C., Mir S.E., Noske D., Van Noorden C.J., Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 2011, 17:4200-4207.
35. Kreahling J.M., Gemmer J.Y., Reed D., Letson D., Bui M., Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol. Cancer Ther. 2012, 11:174-182.
36. Mir S.E., De Witt Hamer P.C., Krawczyk P.M., Balaj L., Claes A., Niers J.M., Van Tilborg A.A., Zwinderman A.H., Geerts D., Kaspers G.J., Peter Vandertop W., Cloos J., Tannous B.A., Wesseling P., Aten J.A., Noske D.P., Van Noorden C.J., Wurdinger T. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18:244-257.
37. Wang H., Huang M., Zhang D.Y., Zhang F. Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. Oncologist 2011, 16:966-979.
38. PosthumaDeBoer J., Wurdinger T., Graat H.C., van Beusechem V.W., Helder M.N., van Royen B.J., Kaspers G.J. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011, 11:156.
39. Magnussen G.I., Holm R., Emilsen E., Rosnes A.K., Slipicevic A., Florenes V.A. High expression of wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 2012, 7:e38254.
40. Backert S., Gelos M., Kobalz U., Hanski M.L., Bohm C., Mann B., Lovin N., Gratchev A., Mansmann U., Moyer M.P., Riecken E.O., Hanski C. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int. J. Cancer 1999, 82:868-874.
41. Kiviharju-af Hallstrom T.M., Jaamaa S., Monkkonen M., Peltonen K., Andersson L.C., Medema R.H., Peehl D.M., Laiho M. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7211-7216.
42. Yoshida T., Tanaka S., Mogi A., Shitara Y., Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann. Oncol. 2004, 15:252-256.
43. Panek R.L., Lu G.H., Klutchko S.R., Batley B.L., Dahring T.K., Hamby J.M., Hallak H., Doherty A.M., Keiser J.A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 283:1433-1444.
44. Palmer B.D., Smaill J.B., Rewcastle G.W., Dobrusin E.M., Kraker A., Moore C.W., Steinkampf R.W., Denny W.A. Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorg. Med. Chem. Lett. 2005, 15:1931-1935.
45. Palmer B.D., Thompson A.M., Booth R.J., Dobrusin E.M., Kraker A.J., Lee H.H., Lunney E.A., Mitchell L.H., Ortwine D.F., Smaill J.B., Swan L.M., Denny W.A. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J. Med. Chem. 2006, 49:4896-4911.
46. Arora S., Bisanz K.M., Peralta L.A., Basu G.D., Choudhary A., Tibes R., Azorsa D.O. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol. Oncol. 2010, 118:220-227.
47. Mizuarai S., Yamanaka K., Itadani H., Arai T., Nishibata T., Hirai H., Kotani H. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol. Cancer 2009, 8:34.
48. Hirai H., Iwasawa Y., Okada M., Arai T., Nishibata T., Kobayashi M., Kimura T., Kaneko N., Ohtani J., Yamanaka K., Itadani H., Takahashi-Suzuki I., Fukasawa K., Oki H., Nambu T., Jiang J., Sakai T., Arakawa H., Sakamoto T., Sagara T., Yoshizumi T., Mizuarai S., Kotani H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 2009, 8:2992-3000.
49. Hashimoto O., Shinkawa M., Torimura T., Nakamura T., Selvendiran K., Sakamoto M., Koga H., Ueno T., Sata M. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006, 6:292.
50. Bridges K.A., Hirai H., Buser C.A., Brooks C., Liu H., Buchholz T.A., Molkentine J.M., Mason K.A., Meyn R.E. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res. 2011, 17:5638-5648.
51. Hirai H., Arai T., Okada M., Nishibata T., Kobayashi M., Sakai N., Imagaki K., Ohtani J., Sakai T., Yoshizumi T., Mizuarai S., Iwasawa Y., Kotani H. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol. Ther. 2010, 9:514-522.
52. Sarcar B., Kahali S., Prabhu A.H., Shumway S.D., Xu Y., Demuth T., Chinnaiyan P. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol. Cancer Ther. 2011, 10:2405-2414.
53. Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., Shumway S.D., Mizuarai S., Hirai H., Maitra A., Hidalgo M. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 2011, 17:2799-2806.
54. Aarts M., Sharpe R., Garcia-Murillas I., Gevensleben H., Hurd M.S., Shumway S.D., Toniatti C., Ashworth A., Turner N.C. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012, 2:524-539.
55. Caretti V., Hiddingh L., Lagerweij T., Schellen P., Koken P.W., Hulleman E., van Vuurden D.G., Vandertop W.P., Kaspers G.J., Noske D.P., Wurdinger T. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol. Cancer Ther. 2013, 12:141-150.
56. Kim M.J., Lee J.Y., Lee S.J. Transient suppression of nuclear Cdc2 activity in response to ionizing radiation. Oncol. Rep. 2008, 19:1323-1329.
57. Suzuki K., Ojima M., Kodama S., Watanabe M. Radiation-induced DNA damage and delayed induced genomic instability. Oncogene 2003, 22:6988-6993.
58. Lorimore S.A., Coates P.J., Wright E.G. Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation. Oncogene 2003, 22:7058-7069.
59. Gorman S., Tosetto M., Lyng F., Howe O., Sheahan K., O'Donoghue D., Hyland J., Mulcahy H., O'Sullivan J. Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. Mutat. Res. 2009, 669:131-138.
60. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
61. Li J., Wang Y., Sun Y., Lawrence T.S. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat. Res. 2002, 157:322-330.
62. Krajewska M., Heijink A.M., Bisselink Y.J., Seinstra R.I., Sillje H.H., de Vries E.G., van Vugt M.A. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2012, (in press). 10.1038/onc.2012.296.
63. Shao C., Deng L., Henegariu O., Liang L., Stambrook P.J., Tischfield J.A. Chromosome instability contributes to loss of heterozygosity in mice lacking p53. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7405-7410.
64. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
65. Fukasawa K., Wiener F., Vande Woude G.F., Mai S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 1997, 15:1295-1302.
66. Duensing A., Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem. Biophys. Res. Commun. 2005, 331:694-700.
67. Rajagopalan H., Nowak M.A., Vogelstein B., Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 2003, 3:695-701.
68. Michor F. Chromosomal instability and human cancer. Philos. Trans. R Soc. Lond. B Biol. Sci. 2005, 360:631-635.
69. Michor F., Iwasa Y., Vogelstein B., Lengauer C., Nowak M.A. Can chromosomal instability initiate tumorigenesis?. Semin. Cancer Biol. 2005, 15:43-49.
70. Kolodner R.D., Putnam C.D., Myung K. Maintenance of genome stability in Saccharomyces cerevisiae. Science 2002, 297:552-557.
71. Shonn M.A., McCarroll R., Murray A.W. Requirement of the spindle checkpoint for proper chromosome segregation in budding yeast meiosis. Science 2000, 289:300-303.
72. Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science 2002, 297:559-565.
73. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38:1043-1048.
74. McClelland S.E., Burrell R.A., Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 2009, 8:3262-3266.
75. Ott K., Vogelsang H., Mueller J., Becker K., Muller M., Fink U., Siewert J.R., Hofler H., Keller G. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin. Cancer Res. 2003, 9:2307-2315.
76. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 2001, 21:4129-4139.
77. Zabludoff S.D., Deng C., Grondine M.R., Sheehy A.M., Ashwell S., Caleb B.L., Green S., Haye H.R., Horn C.L., Janetka J.W., Liu D., Mouchet E., Ready S., Rosenthal J.L., Queva C., Schwartz G.K., Taylor K.J., Tse A.N., Walker G.E., White A.M. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008, 7:2955-2966.
78. Carrassa L., Chila R., Lupi M., Ricci F., Celenza C., Mazzoletti M., Broggini M., Damia G. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012, 11.
79. Guertin A.D., Martin M.M., Roberts B., Hurd M., Qu X., Miselis N.R., Liu Y., Li J., Feldman I., Benita Y., Bloecher A., Toniatti C., Shumway S.D. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int. 2012, 12:45.
80. Russell M., Levin K., Rader J., Belcastro L., Li Y., Martinez D., Pawel B.R., Shumway S.D., Maris J.M., Cole K.A. Combination therapy targeting the Chk1 and Wee1 kinases demonstrates therapeutic efficacy in neuroblastoma. Cancer Res. 2013, 73:776-784.
81. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 2012, 18:64-76.
82. Mollapour M., Tsutsumi S., Donnelly A.C., Beebe K., Tokita M.J., Lee M.J., Lee S., Morra G., Bourboulia D., Scroggins B.T., Colombo G., Blagg B.S., Panaretou B., Stetler-Stevenson W.G., Trepel J.B., Piper P.W., Prodromou C., Pearl L.H., Neckers L. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell 2010, 37:333-343.
83. Iwai A., Bourboulia D., Mollapour M., Jensen-Taubman S., Lee S., Donnelly A.C., Yoshida S., Miyajima N., Tsutsumi S., Smith A.K., Sun D., Wu X., Blagg B.S., Trepel J.B., Stetler-Stevenson W.G., Neckers L. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle 2012, 11:3649-3655.
84. Potapova T.A., Sivakumar S., Flynn J.N., Li R., Gorbsky G.J. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited. Mol. Biol. Cell 2011, 22:1191-1206.